Abstract
SAITO, T., FURUYAMA, T., KYOGOKU, Y., YAMAKAGE, K., ARAKAWA, M. and YOSHINAGA, K. Focal Glomerular Sclerosis in Aminonucleoside Nephropathy. Tohoku J. exp. Med., 1981, 133 (3), 349-360-In an attempt to establish a model of focal glomerular sclerosis (FGS), 17 male Sprague-Dawley rats were i.m. injected with aminonucleoside of puromycin (AN) in a dose of 1mg/100g body weight for 8 consecutive days as one series. Seven rats were treated through the one series only, and followed up for 4 to 8 months after AN loading (Group I). Two months after the first series, the other 10 were given the same injections as the second series. Four rats were killed within one week after the second series because of their intractable debilitation (Group II-a), and the remaining 6 were kept for 4 to 6 months after the second series (Group II-b). Glomeruli involving sclerotic lesions and/or hyaline deposits were 3.8 to 50.7% (mean±S.E., 23.7±6.3%) for Group I, 3.3 to 41.6 % (21.6±8.2%) for Group II-a and 9.3 to 25.0% (17.5±2.7%) for Group II-b. Glomerular sclerosis was closely associated with irreversible proteinuria in the early stage. But, in Group II-a, hyaline deposit was less frequently observed than that in other long maintained groups. Thus, hyaline deposits in this disease usually appeared lagging in time behind the formation of glomerular sclerosis.
